01:50 , May 10, 2019 |  BC Innovations  |  Targets & Mechanisms

The tumor microbiome emerges as a new source of translational opportunities

While the gut microbiome has attracted wide attention for its influence on anti-tumor immunity, a growing body of research suggests microbes living in the tumor itself may play even broader roles in cancer. At least...
19:44 , May 9, 2019 |  BC Extra  |  Clinical News

May 9 Clinical Quick Takes: Polyphor, BMS, Cel-Sci, University of Pittsburgh, Merck, Scholar Rock, Promethera

Polyphor halts Phase III enrollment of pneumonia therapy  Polyphor Ltd. (SIX:POLN) said late Thursday it will suspend enrollment in the Phase III PRISM-MDR and PRISM-UDR trials of pneumonia antibiotic murepavadin (POL7080) after observing a 56%...
20:39 , May 2, 2019 |  BC Innovations  |  Emerging Company Profile

SAB: Human polyclonal antibodies on the hoof

SAB’s platform for producing human polyclonal antibodies directly in cows and goats avoids the limitations of other methods that start from animal or donor-derived antibodies. Therapeutic mAbs and bi- and tri-specific antibodies target no more...
02:24 , Mar 29, 2019 |  BC Innovations  |  Targets & Mechanisms

Next-wave targets at AACR 2019 start filling the blanks in the tumor microenvironment

New and emerging targets at AACR 2019 show cancer researchers are gaining granularity on how to manipulate the tumor microenvironment, a top priority goal for the field. The targets point to emerging strategies for modulating...
19:47 , Mar 19, 2019 |  BC Extra  |  Tools & Techniques

FNIH launches project to improve TB vaccination

Backed by the Bill & Melinda Gates Foundation, the Foundation for the National Institutes of Health launched a project to study a new delivery route to improve the efficacy of the only approved tuberculosis vaccine....
18:03 , Mar 13, 2019 |  BC Innovations  |  Distillery Therapeutics

Inhibiting FERMT2 for lung cancer

DISEASE CATEGORY: Cancer INDICATION: Lung cancer Patient sample, cell culture and mouse studies suggest inhibiting FERMT2 could help treat lung cancer. In patient tissue samples, FERMT2 levels were higher in tumor samples than in adjacent...
01:08 , Feb 1, 2019 |  BC Week In Review  |  Company News

AZ, UPMC in value-based agreement for Brilinta

To reduce out-of-pocket costs for Medicare patients, AstraZeneca plc (LSE:AZN; NYSE:AZN) signed a value-based contract with UPMC Health Plan for Brilinta ticagrelor that links reimbursement of the drug to cardiovascular outcomes following a recent hospitalization...
22:22 , Jan 28, 2019 |  BC Extra  |  Company News

AZ, UPMC in value-based agreement for Brilinta

To reduce out-of-pocket costs for Medicare patients, AstraZeneca plc (LSE:AZN; NYSE:AZN) signed a value-based contract with UPMC Health Plan for Brilinta ticagrelor that links reimbursement of the drug to cardiovascular outcomes following a recent hospitalization...
18:47 , Jan 25, 2019 |  BC Extra  |  Politics & Policy

PhRMA to accept inflation caps

PhRMA is prepared to accept a cap on drug price increases, biopharma executives involved in drafting the trade association’s response to the Trump administration’s drug pricing blueprint told BioCentury. The PhRMA board is considering a...
00:12 , Jan 23, 2019 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Zika virus Cell culture and mouse studies suggest IL-29 and IL-28A could help prevent Zika infection in women. In primary human vaginal and cervical epithelial cells, pretreatment with IL-29 decreased Zika infection compared with...